Brokers Offer Predictions for ARCT FY2025 Earnings

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) – Equities researchers at Cantor Fitzgerald issued their FY2025 earnings per share estimates for shares of Arcturus Therapeutics in a research note issued to investors on Tuesday, January 21st. Cantor Fitzgerald analyst P. Stavropoulos forecasts that the biotechnology company will post earnings per share of ($3.21) for the year. Cantor Fitzgerald currently has a “Overweight” rating on the stock. The consensus estimate for Arcturus Therapeutics’ current full-year earnings is ($2.31) per share.

Separately, HC Wainwright restated a “buy” rating and set a $63.00 price target on shares of Arcturus Therapeutics in a report on Monday, January 13th. Six analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Buy” and a consensus price target of $66.75.

Arcturus Therapeutics Stock Down 1.7 %

Shares of ARCT opened at $17.12 on Thursday. The stock has a market cap of $463.73 million, a PE ratio of -7.71 and a beta of 2.63. Arcturus Therapeutics has a 12-month low of $14.30 and a 12-month high of $45.00. The business has a 50-day simple moving average of $17.28 and a two-hundred day simple moving average of $19.69.

Arcturus Therapeutics (NASDAQ:ARCT) last issued its earnings results on Thursday, November 7th. The biotechnology company reported ($0.26) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.70) by $0.44. Arcturus Therapeutics had a negative net margin of 36.39% and a negative return on equity of 22.39%. The firm had revenue of $41.67 million for the quarter, compared to analyst estimates of $49.16 million. During the same quarter last year, the business posted ($0.61) earnings per share.

Hedge Funds Weigh In On Arcturus Therapeutics

Hedge funds have recently bought and sold shares of the company. nVerses Capital LLC acquired a new stake in Arcturus Therapeutics during the 3rd quarter worth about $42,000. China Universal Asset Management Co. Ltd. boosted its position in shares of Arcturus Therapeutics by 64.4% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 5,201 shares of the biotechnology company’s stock valued at $121,000 after purchasing an additional 2,038 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. acquired a new stake in Arcturus Therapeutics during the second quarter worth approximately $142,000. Point72 DIFC Ltd bought a new stake in Arcturus Therapeutics in the second quarter worth approximately $188,000. Finally, SG Americas Securities LLC acquired a new position in Arcturus Therapeutics in the third quarter valued at approximately $191,000. Institutional investors own 94.54% of the company’s stock.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.